Drug Trial Radar · NCT06565689
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
May 9, 2023
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Excyte Biopharma LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to provide a basis for further clinical development of YK012.
Conditions
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
YK012Drug
YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of subjects with adverse events (AEs) and/or serious adverse events (SAEs)Time frame: From the first infusion of YK012 until 28 Days after end of treatment
- The incidence and profile of dose-limiting toxicity (DLT)Time frame: 28 days after the first dose
- The maximum tolerated dose and/or the recommended dose for further clinical trialTime frame: 28 days after the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.